Psychotic disorders in children and adolescents: A primer on contemporary evaluation and management

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 16, Issue 2, 2014, Pages

  Stevens, Jonathan R ^a,b   Prince, Jefferson B ^c,d   Prager, Laura M ^d,e   Stern, Theodore A ^d,e  

^a Henry Ford   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c NORTH SHORE MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; ILOPERIDONE; LURASIDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; SEROTONIN; THIOXANTHENE DERIVATIVE; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; ARTICLE; BEHAVIOR; BIPOLAR DISORDER; BLURRED VISION; CANNABIS USE; CHILD; CHILDHOOD DISEASE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DELUSION; DIAGNOSTIC ACCURACY; DROWSINESS; DSM-5; DYSKINESIA; DYSLIPIDEMIA; DYSTONIA; EARLY INTERVENTION; ELECTROENCEPHALOGRAPHY; ENVIRONMENTAL FACTOR; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FAMILY HISTORY; GENETIC RISK; HALLUCINATION; HUMAN; MAJOR DEPRESSION; MENTAL HEALTH CARE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROIMAGING; NEUROLEPTIC MALIGNANT SYNDROME; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PERSONALITY TEST; PREVALENCE; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SELF REPORT; SOCIOECONOMICS; XEROSTOMIA;

EID: 84901990024     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13f01514     Document Type: Article

References (92)

1. Freudenreich O. Psychotic Disorders: A Practical Guide. Philadelphia, PA: Lippincott Williams and Wilkens; 2008.
2. van Os J, Linscott RJ, Myin-Germeys I, et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis-proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179-195. PubMed
3. Poulton R, Caspi A, Moffitt TE, et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry. 2000;57(11):1053-1058. doi:10.1001/archpsyc.57.11.1053 PubMed
4. Bartels-Velthuis AA, Jenner JA, van de Willige G, et al. Prevalence and correlates of auditory vocal hallucinations in middle childhood. Br J Psychiatry. 2010;196(1):41-46. doi:10.1192/bjp.bp.109.065953 PubMed
5. Horwood J, Salvi G, Thomas K, et al. IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. Br J Psychiatry. 2008;193(3):185-191. doi:10.1192/bjp.bp.108.051904 PubMed
6. Laurens KR, Hodgins S, Maughan B, et al. Community screening for psychotic-like experiences and other putative antecedents of schizophrenia in children aged 9-12 years. Schizophr Res. 2007;90(1-3):130-146. doi:10.1016/j.schres.2006.11.006 PubMed
7. Yung AR, Nelson B, Baker K, et al. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust N Z J Psychiatry. 2009;43(2):118-128. doi:10.1080/00048670802607188 PubMed
8. Kelleher I, Harley M, Murtagh A, et al. Are screening instruments valid for psychotic-like experiences? a validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull. 2011;37(2):362-369. doi:10.1093/schbul/sbp057 PubMed
9. Kelleher I, Corcoran P, Keeley H, et al. Psychotic symptoms and population risk for suicide attempt: a prospective cohort study. JAMA Psychiatry. 2013;70(9):940-948. doi:10.1001/jamapsychiatry.2013.140 PubMed
10. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. doi:10.1371/journal.pmed.0020141 PubMed
11. McClellan J, Werry J; American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2001;40(suppl):4S-23S. doi:10.1097/00004583-200107001-00002 PubMed
12. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721-730. doi:10.1001/archpsyc.63.7.721 PubMed
13. Maloney AE, Yakutis LJ, Frazier JA. Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia. Child Adolesc Psychiatr Clin N Am. 2012;21(4):885-909. doi:10.1016/j.chc.2012.07.011 PubMed
14. Pavuluri MN, Herbener ES, Sweeney JA. Psychotic symptoms in pediatric bipolar disorder. J Affect Disord. 2004;80(1):19-28. doi:10.1016/S0165-0327(03)00053-3 PubMed
15. Kaufman J, Birmaher B, Clayton S, et al. Case study: trauma-related hallucinations. J Am Acad Child Adolesc Psychiatry. 1997;36(11):1602-1605. PubMed
16. Unenge Hallerbäck M, Lugnegård T, Gillberg C. Is autism spectrum disorder common in schizophrenia? Psychiatry Res. 2012;198(1):12-17. doi:10.1016/j.psychres.2012.01.016 PubMed
17. van de Riet EH, Esseveld MM, Cuypers L, et al. Anti-NMDAR encephalitis: a new, severe and challenging enduring entity. Eur Child Adolesc Psychiatry. 2013;22(5):319-323. PubMed
18. Freudenreich O, Schulz SC, Goff DC. Initial medical work-up of first-episode psychosis: a conceptual review. Early Interv Psychiatry. 2009;3(1):10-18. doi:10.1111/j.1751-7893.2008.00105.x PubMed
19. Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry. 2002;41(5):538-545. doi:10.1097/00004583-200205000-00011 PubMed
20. McDonell M, McClellan J. Early-onset schizophrenia. In: Mash E, Barkley R, eds. Assessment of Childhood Disorders. 4th ed. New York, NY: Guilford Press; 2007:526-550.
21. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(suppl 3):S162-S167. doi:10.1055/s-2003-45125 PubMed
22. Thomas LE, Woods SW. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment. Child Adolesc Psychiatr Clin N Am. 2006;15(1):109-133. doi:10.1016/j.chc.2005.08.011 PubMed
23. Bearden CE, Wu KN, Caplan R, et al. Thought disorder and communication deviance as predictors of outcome in youth at clinical high risk for psychosis. J Am Acad Child Adolesc Psychiatry. 2011;50(7):669-680. doi:10.1016/j.jaac.2011.03.021 PubMed
24. Karp BI, Garvey M, Jacobsen LK, et al. Abnormal neurologic maturation in adolescents with early-onset schizophrenia. Am J Psychiatry. 2001;158(1):118-122. doi:10.1176/appi.ajp.158.1.118 PubMed
25. Kumra S, Sporn A, Hommer DW, et al. Smooth pursuit eye-tracking impairment in childhood-onset psychotic disorders. Am J Psychiatry. 2001;158(8):1291-1298. doi:10.1176/appi.ajp.158.8.1291 PubMed
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Press; 2013.
27. DelBello MP, Lopez-Larson MP, Soutullo CA, et al. Effects of race on psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2001;11(1):95-103. doi:10.1089/104454601750143528 PubMed
28. Kodish I, McClellan J. In: Hersen M, Reitman D, eds. Handbook of Psychological Assessment, Case Conceptualization, and Treatment: Vol. 2, Children and Adolescents. Hoboken, NJ: John Wiley & Sons; 2008:405-443.
29. Asarnow RF, Nuechterlein KH, Fogelson D, et al. Schizophrenia and schizophrenia-spectrum personality disorders in the first-degree relatives of children with schizophrenia: the UCLA family study. Arch Gen Psychiatry. 2001;58(6):581-588. doi:10.1001/archpsyc.58.6.581 PubMed
30. Gogtay N, Sporn A, Clasen LS, et al. Structural brain MRI abnormalities in healthy siblings of patients with childhood-onset schizophrenia. Am J Psychiatry. 2003;160(3):569-571. doi:10.1176/appi.ajp.160.3.569 PubMed
31. Keshavan MS, Diwadkar VA, Montrose DM, et al. Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study. World Psychiatry. 2004;3(3):163-168. PubMed
32. Byrne M, Agerbo E, Bennedsen B, et al. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res. 2007;97(1-3):51-59. doi:10.1016/j.schres.2007.07.018 PubMed
33. Fish B, Kendler KS. Abnormal infant neurodevelopment predicts schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. 2005;15(3):348-361. doi:10.1089/cap.2005.15.348 PubMed
34. Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci. 2011;29(3):251-258. doi:10.1016/j.ijdevneu.2010.10.003 PubMed
35. Rapoport JL, Giedd JN, Blumenthal J, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 1999;56(7):649-654. doi:10.1001/archpsyc.56.7.649 PubMed
36. Rapoport JL, Addington AM, Frangou S, et al. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10(5):434-449. doi:10.1038/sj.mp.4001642 PubMed
37. Greenstein D, Lerch J, Shaw P, et al. Childhood onset schizophrenia: cortical brain abnormalities as young adults. J Child Psychol Psychiatry. 2006;47(10):1003-1012. doi:10.1111/j.1469-7610.2006.01658.x PubMed
38. Steen RG, Mull C, McClure R, et al. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006;188(6):510-518. doi:10.1192/bjp.188.6.510 PubMed
39. Ahmed AO, Buckley PF, Hanna M. Neuroimaging schizophrenia: a picture is worth a thousand words, but is it saying anything important? Curr Psychiatry Rep. 2013;15(3):345. doi:10.1007/s11920-012-0345-0 PubMed
40. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385(6617):634-636. doi:10.1038/385634a0 PubMed
41. Clinton SM, Haroutunian V, Davis KL, et al. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2003;160(6):1100-1109. doi:10.1176/appi.ajp.160.6.1100 PubMed
42. Millichap JJ, Goldstein JL, Laux LC, et al. Ictal asystole and anti-N-methyl-d-aspartate receptor antibody encephalitis. Pediatrics. 2011;127(3):e781-e786. doi:10.1542/peds.2010-2080 PubMed
43. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99(4):425-430. doi:10.1111/j.1360-0443.2004.00683.x PubMed
44. Schimmelmann BG, Conus P, Cotton SM, et al. Cannabis use disorder and age at onset of psychosis-a study in first-episode patients. Schizophr Res. 2011;129(1):52-56. doi:10.1016/j.schres.2011.03.023 PubMed
45. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657-E2664. doi:10.1073/pnas.1206820109 PubMed
46. Kolliakou A, Joseph C, Ismail K, et al. Why do patients with psychosis use cannabis and are they ready to change their use? Int J Dev Neurosci. 2011;29(3):335-346. doi:10.1016/j.ijdevneu.2010.11.006 PubMed
47. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-328. doi:10.1016/S0140-6736(07)61162-3 PubMed
48. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008;165(4):490-496. doi:10.1176/appi.ajp.2007.07071110 PubMed
49. Freudenreich O, Goff DC. Psychotic patients. In: Stern TA, Fricchione GH, eds. Massachusetts General Hospital Handbook of General Hospital Psychiatry. Amsterdam, The Netherlands: Elsevier Science Publishers; 2010. doi:10.1016/B978-1-4377-1927-7.00012-1
50. Manchanda R, Norman R, Malla A, et al. EEG abnormalities and two year outcome in first episode psychosis. Acta Psychiatr Scand. 2005;111(3):208-213. doi:10.1111/j.1600-0447.2004.00490.x PubMed
51. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA. 1999;282(1):36-39. doi:10.1001/jama.282.1.36 PubMed
52. Structural neuroimaging in first-episode psychosis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Feb. 24 p. (technology appraisal guidance; no. 136). http://www.guideline.gov/content.aspx?id=12284. Accessed December 4, 2013.
53. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975-983. doi:10.1001/archpsyc.62.9.975 PubMed
54. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011;(6):CD004718. PubMed
55. Ruhrmann S, Schultze-Lutter F, Maier W, et al. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry. 2005;20(1):1-6. doi:10.1016/j.eurpsy.2004.11.001 PubMed
56. Stevens JR, Prince JB. Schooling students with psychotic disorders. Child Adolesc Psychiatr Clin N Am. 2012;21(1):187-200, xi. doi:10.1016/j.chc.2011.09.008 PubMed
57. Turkington D, Kingdon D, Turner T; Insight into Schizophrenia Research Group. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. Br J Psychiatry. 2002;180(6):523-527. doi:10.1192/bjp.180.6.523 PubMed
58. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185(4):291-297. doi:10.1192/bjp.185.4.291 PubMed
59. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921-928. doi:10.1001/archpsyc.59.10.921 PubMed
60. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011;(6):CD002831. PubMed
61. Jones C, Cormac I, Silveira da Mota Neto JI, et al. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004;(4):CD000524. PubMed
62. Lee RS, Redoblado-Hodge MA, Naismith SL, et al. Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. Psychol Med. 2013;43(6):1161-1173. PubMed
63. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-1441. doi:10.1176/appi.ajp.2008.07061035 PubMed
64. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60-70. doi:10.1097/CHI.0b013e3181900404 PubMed
65. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70(12):1179-1187. doi:10.1016/j.biopsych.2011.06.021 PubMed
66. Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22(5):327-342. doi:10.1089/cap.2011.0092 PubMed
67. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194(2):158-164. doi:10.1192/bjp.bp.107.046177 PubMed
68. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621. doi:10.1089/cap.2008.0144 PubMed
69. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007;46(8):969-978. doi:10.1097/CHI.0b013e3180691779 PubMed
70. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420-1431. doi:10.1176/appi.ajp.2008.08050756 PubMed
71. Yan J. FDA advisors back additional antipsychotics for use in teens. Psychiatr News. 2009;44(13):1-29.
72. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128. doi:10.4088/JCP.v63n1206 PubMed
73. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41. doi:10.1056/NEJM199601043340109 PubMed
74. Lasser RA, Schooler NR, Kujawa M, et al. A new psychosocial tool for gaining patient understanding and acceptance of long-acting injectable antipsychotic therapy. Psychiatry (Edgmont). 2009;6(4):22-27. PubMed
75. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol. 2005;19(suppl):5-14. doi:10.1177/0269881105056513 PubMed
76. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132. doi:10.1176/appi.ajp.160.6.1125 PubMed
77. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006;67(8):1194-1203. doi:10.4088/JCP.v67n0804 PubMed
78. Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol. 2005;20(4):213-221. doi:10.1097/00004850-200507000-00004 PubMed
79. Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7(3):247-254. doi:10.1111/eip.12027 PubMed
80. Celano CM, Beach SR, Huffman JC, et al. Side effects profiles of psychotropic medications from cardiovascular and other side effects of psychotropic medications. In: Stern TA, Herman JB, Gorrindo T, eds. The Massachusetts General Hospital Psychiatry Update and Board Preparation. 3rd ed. Boston, MA: MGH Psychiatry Academy Publishing; 2012.
81. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15(1):177-206. doi:10.1016/j.chc.2005.08.007 PubMed
82. Schimmelmann BG, Schmidt SJ, Carbon M, et al. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry. 2013 Mar;26(2):219-230. doi: 10.1097/YCO.0b013e32835dcc2a PubMed
83. Correll CU, Kane JM Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647-656. doi:10.1089/cap.2006.0117 PubMed
84. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144-158. doi:10.1016/j.eurpsy.2010.09.011 PubMed
85. Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol. 2005;15(6):893-900. doi:10.1089/cap.2005.15.893 PubMed
86. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology (Berl). 1979;61(3):261-262. doi:10.1007/BF00432269 PubMed
87. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-1097. doi:10.1001/archpsyc.1996.01830120020005 PubMed
88. Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33(5):658-663. doi:10.1097/00004583-199406000-00006 PubMed
89. Mattai A, Fung L, Bakalar J, et al. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol. 2009;24(7):584-589. doi:10.1002/hup.1056 PubMed
90. Eggers C, Bunk D, Krause D. Schizophrenia with onset before the age of eleven: clinical characteristics of onset and course. J Autism Dev Disord. 2000;30(1):29-38. doi:10.1023/A:1005408010797 PubMed
91. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-799. doi:10.1176/appi.ajp.163.5.790 PubMed
92. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-154. doi:10.1001/archgenpsychiatry.2009.192 PubMed